NBIX Neurocrine Biosciences, Inc. - Fundamental Analysis
NEUTRAL
NBIX Stock | Fundamental Analysis & Investment Insights
NASDAQ
•
Healthcare
•
Drug Manufacturers - Specialty & Generic
Current Price
$140.6
Analyst Target
$179.7
+27.8% Upside
52W High
$160.18
52W Low
$84.23
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Neurocrine Biosciences exhibits strong financial health with an exceptionally high Altman Z-Score (21386045760.0), indicating negligible bankruptcy risk, but a weak Piotroski F-Score of 4/9 suggests only stable operational performance. The company shows robust profitability and growth, with 27.8% YoY revenue growth and 64.5% earnings growth, supported by solid margins and low leverage. However, the stock trades at a premium valuation (P/E 33.56 vs. sector avg 35.94) above its Graham Number of $53.29 and even its growth-based intrinsic value of $123.61, while insider selling and mixed earnings surprises temper optimism. Analysts maintain a strong_buy consensus, but recent price performance and technical trend (0/100) indicate near-term bearish momentum.
Key Strengths
Exceptionally high Altman Z-Score indicates near-zero risk of financial distress
Strong profitability with gross margin of 63.21%, operating margin of 30.10%, and ROE of 14.96%
Robust revenue and earnings growth: 27.8% YoY revenue growth and 64.5% YoY earnings growth
Low financial leverage with Debt/Equity ratio of 0.16 and strong liquidity (Current Ratio: 3.38)
Analyst consensus is strong_buy with a high target price of $179.70, implying ~28% upside
Key Risks
Piotroski F-Score of 4/9 indicates weak operational momentum and financial stability concerns
Stock trades at a premium: current price ($140.60) exceeds both Graham Number ($53.29) and intrinsic value ($123.61)
Insider sentiment is bearish with $23.21M in net insider sales over the last 6 months and no buys
Earnings surprise history is inconsistent, with only 2 out of last 4 quarters beating estimates and an average negative surprise of -7.16%
Technical trend score of 0/100 and recent price declines (-7.5% over 1M, -3.2% over 1W) suggest weakening momentum
AI Fair Value Estimate
Based on comprehensive analysis
$123.61
-12.1% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare NBIX against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations